Virus-Like Particle-Based Multiserotype Quartet Vaccine of Dengue Envelope Protein Domain III Elicited Potent Anti-Dengue Responses

IF 5.4 2区化学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biomacromolecules Pub Date : 2025-07-14 DOI:10.1021/acs.biomac.5c00459

Jirayu Boonyakida , Mami Matsuda , Ryosuke Suzuki , Krishna Raja Muthuraman , Enoch Y. Park

{"title":"Virus-Like Particle-Based Multiserotype Quartet Vaccine of Dengue Envelope Protein Domain III Elicited Potent Anti-Dengue Responses","authors":"Jirayu Boonyakida , Mami Matsuda , Ryosuke Suzuki , Krishna Raja Muthuraman , Enoch Y. Park","doi":"10.1021/acs.biomac.5c00459","DOIUrl":null,"url":null,"abstract":"<div><div>In this study, we presented two strategies for designing an envelope domain III (EDIII)-based tetravalent dengue virus (DENV) vaccine. The first approach was conjugation of the EDIIIs from all four DENV serotypes to a norovirus-like particle (NoV-LP) scaffold, yielding the NoV::tetEDIII vaccine. The second approach linked the EDIIIs of all four serotypes into a single polypeptide chain, which was also conjugated to the NoV-LP scaffold by using the SpyTag/SpyCatcher system, creating the NoV::quartetEDIII vaccine. These tetravalent DENV vaccines were evaluated for their immunogenicity against all DENV serotypes. Both vaccines elicited strong antibody responses against all serotypes in a prime-and-boost immunization regimen. Furthermore, the single-round infectious particle (SRIP) assay demonstrated that these antibodies had neutralizing capabilities superior to those of traditional subunit vaccines. Our study proposes a promising DENV vaccine strategy that may protect against all four serotypes, potentially promoting public health efforts to prevent and control dengue disease.</div></div><div><div><span><figure><span><img><ol><li><span><span>Download: <span>Download high-res image (99KB)</span></span></span></li><li><span><span>Download: <span>Download full-size image</span></span></span></li></ol></span></figure></span></div></div>","PeriodicalId":30,"journal":{"name":"Biomacromolecules","volume":"26 7","pages":"Pages 4449-4463"},"PeriodicalIF":5.4000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomacromolecules","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/org/science/article/pii/S152577972500279X","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In this study, we presented two strategies for designing an envelope domain III (EDIII)-based tetravalent dengue virus (DENV) vaccine. The first approach was conjugation of the EDIIIs from all four DENV serotypes to a norovirus-like particle (NoV-LP) scaffold, yielding the NoV::tetEDIII vaccine. The second approach linked the EDIIIs of all four serotypes into a single polypeptide chain, which was also conjugated to the NoV-LP scaffold by using the SpyTag/SpyCatcher system, creating the NoV::quartetEDIII vaccine. These tetravalent DENV vaccines were evaluated for their immunogenicity against all DENV serotypes. Both vaccines elicited strong antibody responses against all serotypes in a prime-and-boost immunization regimen. Furthermore, the single-round infectious particle (SRIP) assay demonstrated that these antibodies had neutralizing capabilities superior to those of traditional subunit vaccines. Our study proposes a promising DENV vaccine strategy that may protect against all four serotypes, potentially promoting public health efforts to prevent and control dengue disease.

Download: Download high-res image (99KB)
Download: Download full-size image

查看原文本刊更多论文

基于病毒样颗粒的登革热包膜蛋白结构域III多血清型四重奏疫苗引发了有效的抗登革热反应。

在这项研究中，我们提出了设计基于包膜结构域III （EDIII）的四价登革热病毒（DENV）疫苗的两种策略。第一种方法是将所有四种DENV血清型的ediii与诺如病毒样颗粒（NoV- lp）支架结合，产生NoV::tetEDIII疫苗。第二种方法将所有四种血清型的ediii连接成一条多肽链，并使用SpyTag/SpyCatcher系统将其偶联到NoV- lp支架上，从而产生NoV::quartetEDIII疫苗。评估了这些四价DENV疫苗对所有DENV血清型的免疫原性。这两种疫苗在初始和增强免疫方案中都能引起针对所有血清型的强抗体反应。此外，单轮感染颗粒（SRIP）试验表明，这些抗体具有优于传统亚单位疫苗的中和能力。我们的研究提出了一种有希望的DENV疫苗策略，它可以预防所有四种血清型，有可能促进预防和控制登革热的公共卫生努力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomacromolecules 化学-高分子科学

CiteScore

10.60

自引率

4.80%

发文量

417

审稿时长

1.6 months

期刊介绍： Biomacromolecules is a leading forum for the dissemination of cutting-edge research at the interface of polymer science and biology. Submissions to Biomacromolecules should contain strong elements of innovation in terms of macromolecular design, synthesis and characterization, or in the application of polymer materials to biology and medicine. Topics covered by Biomacromolecules include, but are not exclusively limited to: sustainable polymers, polymers based on natural and renewable resources, degradable polymers, polymer conjugates, polymeric drugs, polymers in biocatalysis, biomacromolecular assembly, biomimetic polymers, polymer-biomineral hybrids, biomimetic-polymer processing, polymer recycling, bioactive polymer surfaces, original polymer design for biomedical applications such as immunotherapy, drug delivery, gene delivery, antimicrobial applications, diagnostic imaging and biosensing, polymers in tissue engineering and regenerative medicine, polymeric scaffolds and hydrogels for cell culture and delivery.